Fundamentals and stats

Key facts

Market capitalization—
Founded—
CEO—
Website—
About

Vaxil Bio Ltd. is a biotechnology company engaged in the development of signal peptide-based immunotherapies for the treatment of cancer and infectious diseases. Its pipeline consists of ImMucin, SPmAb2, SPmAb6, and MTbuVax. The company was founded on July 26, 2006 and is headquartered in Toronto, Canada.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
VXL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company